Learn about innovative programs and resources available through the National MS Society designed to support individuals through the changing journey of MS. Discover the Society’s updated online presence, expanded resources and strategic partnerships. Understand the progress the Society is making in the areas of diversity, equity, inclusion, health literacy and health equity.
After an expansion from zero FDA-approved therapies to 3 in the span of a just couple of years, NMOSD has seen remarkable advancement in the ability to treat patients effectively. With knowledge continuing to expand each day, it is critical that clinicians are fully equipped with the most up-to-date optimized diagnostic and management strategies to apply them directly to patient care. To ensure clinicians have the information and tools to appropriately integrate these advances into practice, this unique symposium is structured around actual questions submitted by neurologists who treat but do not specialize in NMOSD to capture the most prevalent real challenges faced in the clinic today.
This CME/CE activity will highlight the importance of targeting pathways of disease progression in early MS, including the developing role of BTK inhibitors as brain penetrant DMTs that offer opportunities that disarm both the peripheral (i.e., lymphocyte) and central, chronically activated (i.e., microglia/macrophage) cells that are dysregulated in MS. By targeting multiple biological processes that include B-cell and macrophage activation, BTK inhibitors may potentially mitigate early disease activity, as well as activity across the spectrum of MS.
During this CE dinner symposium, experts will present didactic information, review cases of NMOSD, and engage in a panel discussion to summarize evidence-based diagnostic criteria and best practices that aid in the differential diagnosis of NMOSD. This program will aid clinicians in therapeutic decision-making regarding the use of current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and mode of administration. Finally, faculty will examine the interprofessional approaches to diagnose and manage patients with NMOSD.
Bruton tyrosine kinase (BTK) inhibitors are an emerging class of DMTs that reach therapeutic concentrations in the central nervous system and affect processes mediated by B cells and myeloid cells—contributors to the inflammation and neurodegeneration that drive MS.
Join PeerView for this live event, where experts will share stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well the latest data on the four BTK inhibitors in phase 3 clinical trials.
Join Dr Dalia Rotstein, Dr Eoin Flanagan and Dr Jeffrey Bennett as they examine evidence-based approaches to achieve early and accurate diagnosis of NMOSD, leading to appropriate treatment selection. They will explore the latest clinical data on current and emerging treatments, and discuss multidisciplinary strategies to mitigate the clinical burden of NMOSD and improve patient quality of life.
Pre-registration is not required to attend this symposium.
Improved understanding of MS pathogenesis has led to the development of biomarkers and imaging modalities that can monitor disease progression and treatment response. The promise of data-driven personalized care makes it important for clinicians to stay updated on advances in biomarkers and imaging. At this event, experts will cover the data on these new and emerging biomarkers and discuss ways to incorporate biomarker findings into treatment decisions to empower patients and improve outcomes.
Significant advances in multiple sclerosis (MS) treatment have paved the way for patients to live long, healthy lives. However, growing evidence indicates that Black and African American patients experience more severe disease course. The heavier burden for these patients, along with the growing number of MS treatment options, reveals an essential need to close gaps in MS care. Join our renowned panel of experts for this lively discussion to ensure optimal outcomes and quality of life for your patients.